Universal Biosensors (ASX:UBI) share price falls despite positive update

The Universal Biosensors (ASX: UBI) share price is in negative territory today despite a positive update. We take a closer look.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Universal Biosensors Inc (ASX: UBI) share price has spent the day in negative territory today despite the company announcing a new distribution deal.

During the early afternoon trade, the medical diagnostics company's shares are swapping hands for 69 cents, down 1.4%. In comparison, the All Ordinaries Index (ASX: XAO) is sitting at 7,350 points, up 0.4%.

falling asx share price represented by woman making sad face

Image source: Getty Images

What did Universal Biosensors announce?

In today's statement, Universal Biosensors advised it has entered into an exclusive distribution agreement with Grapeworks NZ Limited.

The arrangement will see Universal Biosensors supply its wine testing platform device, Sentia for the New Zealand market. The deal will last for 5 years, provided initial and minimum annual purchase volumes are met. Furthermore, the contract will be subject to the usual customary conditions with attached renewal options available to both parties.

The latest agreement follows the company's progress in delivering its Sentia products across global markets since March 2021.

During the last couple of months, Universal Biosensors has secured distribution deals in Australia, the United States, New Zealand, Canada, Chile and South Africa. This has provided the company with access to over 14,000 wineries, reflecting strong demand for its product.

What did management say?

Universal Biosensors CEO John Sharman welcomed the outcome, saying:

Grapeworks is UBI's exclusive distribution partner for Sentia in Australia, so for them to extend our agreement to cover New Zealand's 500+ wineries demonstrate a strong financial commitment and belief in the future success of Sentia.

Grapeworks NZ managing director Malcolm Wilson went on to add:

Sentia has been well received by our Australian customers. We have been doing our due diligence on an expansion into New Zealand and believe that Sentia is a great product to spearhead our launch.

Universal Biosensors share price review

The Universal Biosensors share price has performed considerably well, gaining close to 240% over the past year. The company's shares recently reached a multi-year high of 84.5 cents earlier this month.

Based on the current share price, Universal Biosensors commands a market capitalisation of $119 million, with 177 million shares outstanding.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

A group of people in a corporate setting do a collective high five.
Healthcare Shares

ASX 300 healthcare stock outperforming today on 'strategic' leadership news

The ASX healthcare stock announced the outcome of its CEO recruitment drive this morning.

Read more »

Cropped shot of a young female scientist working on her computer in the laboratory.
Healthcare Shares

Could Telix shares be a millionaire-maker stock?

Telix looks a compelling growth story, with brokers eyeing more than 150% upside.

Read more »

A child covering his eyes hiding from a toy bear.
Healthcare Shares

Down 20% in 2026, is now the time to buy CSL shares?

CSL shares hit a new multi-year low as the 2026 decline deepens.

Read more »

Scientists in white coats look disappointed.
Healthcare Shares

Down 87% since Thursday, why is this ASX 300 healthcare stock sliding again today?

The ASX healthcare share has plunged more than 87% in five trading days.

Read more »

Female scientist working in a laboratory.
Healthcare Shares

Which ASX biotech's shares have jumped more than 10% on positive clinical trial news?

A potential cancer treatment is progressing.

Read more »

Man jumps for joy in front of a background of a rising stocks graphic.
Healthcare Shares

3 ASX healthcare stocks tipped to soar over 100% higher this year

These ASX shares are on my radar this week.

Read more »

Scientists working in the laboratory and examining results.
Opinions

3 reasons to buy CSL shares today

The ASX biotech company has great growth potential this year.

Read more »

a man lies on his back on grass with his eyes shut and a contented look on his face as though he is dreaming
Broker Notes

With global populations ageing, are ResMed shares a good buy today?

A leading expert delivers his verdict on the outlook for ResMed shares.

Read more »